HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 09-16-2005, 04:46 AM   #1
*_Christine MH_*
Guest
 
Posts: n/a
BCIRG Sanofi Aventis Press Release

A new regime, herceptin, carboplatin, and taxotere followed by a year of herceptin was 39% more effective than the control treatment AC->taxotere in preventing recurrences, while AC->taxotere+herceptin was 55% more effective in preventing recurrences than the control treatment. This is an interim analysis and it is not clear at this time whether the difference between the two experimental arms is statistically significant, although it appears that the taxotere + herceptin + carboplatin arm has not experienced more problems with cardiotoxicity than the control arm, which did not receive herceptin. This is an ongoing analysis and an improvement in overall survival has not yet been demonstrated. More details will come out in San Antonio in December.
  Reply With Quote
Old 09-16-2005, 04:51 AM   #2
*_Christine MH_*
Guest
 
Posts: n/a
Oh, I should add that the AC->(taxotere+herceptin) was also followed by a year of herceptin.
  Reply With Quote
Old 09-19-2005, 01:59 PM   #3
athena453
Senior Member
 
athena453's Avatar
 
Join Date: Sep 2005
Location: Virginia
Posts: 53
Smile

My onc has me on taxotere, carboplatin and herceptin for at least a year (pending Hera results) following AC for stage 3C. I could not have been happier when these results were published.
AM
athena453 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 12:44 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter